Lora L Sabin1, Mary Bachman DeSilva, Christopher J Gill, Li Zhong, Taryn Vian, Wubin Xie, Feng Cheng, Keyi Xu, Guanghua Lan, Jessica E Haberer, David R Bangsberg, Yongzhen Li, Hongyan Lu, Allen L Gifford. 1. *Center for Global Health and Development, Boston University, Boston, MA; †Department of Global Health, Boston University School of Public Health, Boston, MA; ‡FHI 360, Beijing, China; §Research Center for Public Health (TPHRC), School of Medicine, Tsinghua University, Beijing, China; ‖WHO Collaborating Center for Comprehensive Management of HIV Treatment and Care, Ditan Hospital, Beijing, China; ¶AIDS Division, Guangxi Centers for Disease Control and Prevention, Nanning, China; #Center for Global Health, Massachusetts General Hospital, Boston, MA; **Department of Health Policy and Management, Boston University School of Public Health, Boston, MA; and ††Edith Nourse Rogers Memorial VA Hospital, Bedford, MA.
Abstract
BACKGROUND: Real-time adherence monitoring is now possible through medication storage devices equipped with cellular technology. We assessed the effect of triggered cell phone reminders and counseling using objective adherence data on antiretroviral therapy (ART) adherence among Chinese HIV-infected patients. METHODS: We provided ART patients in Nanning, China, with a medication device (Wisepill) to monitor their ART adherence electronically. After 3 months, we randomized subjects within optimal (≥95%) and suboptimal (<95%) adherence strata to intervention vs. control arms. In months 4-9, intervention subjects received individualized reminders triggered by late dose taking (no device opening by 30 minutes past dose time) and counseling using device-generated data. Controls received no reminders or data-informed counseling. We compared postintervention proportions achieving optimal adherence, mean adherence, and clinical outcomes. RESULTS: Of 120 subjects enrolled, 116 (96.7%) completed the trial. Preintervention optimal adherence was similar in intervention vs. control arms (63.5% vs. 58.9%, respectively; P = 0.60). In the last intervention month, 87.3% vs. 51.8% achieved optimal adherence [risk ratio (RR): 1.7, 95% confidence interval (CI): 1.3 to 2.2] and mean adherence was 96.2% vs. 89.1% (P = 0.003). Among preintervention suboptimal adherers, 78.3% vs. 33.3% (RR: 2.4, CI: 1.2 to 4.5) achieved optimal adherence and mean adherence was 93.3% vs. 84.7% (P = 0.039). Proportions were 92.5% and 62.9% among optimal adherers, respectively (RR: 1.5, CI: 1.1 to 1.9) and mean adherence was 97.8% vs. 91.7% (P = 0.028). Postintervention clinical outcomes were not significant. CONCLUSIONS: Real-time reminders significantly improved ART adherence in this population. This approach seems promising for managing HIV and other chronic diseases and warrants further investigation and adaptation in other settings.
RCT Entities:
BACKGROUND: Real-time adherence monitoring is now possible through medication storage devices equipped with cellular technology. We assessed the effect of triggered cell phone reminders and counseling using objective adherence data on antiretroviral therapy (ART) adherence among Chinese HIV-infectedpatients. METHODS: We provided ARTpatients in Nanning, China, with a medication device (Wisepill) to monitor their ART adherence electronically. After 3 months, we randomized subjects within optimal (≥95%) and suboptimal (<95%) adherence strata to intervention vs. control arms. In months 4-9, intervention subjects received individualized reminders triggered by late dose taking (no device opening by 30 minutes past dose time) and counseling using device-generated data. Controls received no reminders or data-informed counseling. We compared postintervention proportions achieving optimal adherence, mean adherence, and clinical outcomes. RESULTS: Of 120 subjects enrolled, 116 (96.7%) completed the trial. Preintervention optimal adherence was similar in intervention vs. control arms (63.5% vs. 58.9%, respectively; P = 0.60). In the last intervention month, 87.3% vs. 51.8% achieved optimal adherence [risk ratio (RR): 1.7, 95% confidence interval (CI): 1.3 to 2.2] and mean adherence was 96.2% vs. 89.1% (P = 0.003). Among preintervention suboptimal adherers, 78.3% vs. 33.3% (RR: 2.4, CI: 1.2 to 4.5) achieved optimal adherence and mean adherence was 93.3% vs. 84.7% (P = 0.039). Proportions were 92.5% and 62.9% among optimal adherers, respectively (RR: 1.5, CI: 1.1 to 1.9) and mean adherence was 97.8% vs. 91.7% (P = 0.028). Postintervention clinical outcomes were not significant. CONCLUSIONS: Real-time reminders significantly improved ART adherence in this population. This approach seems promising for managing HIV and other chronic diseases and warrants further investigation and adaptation in other settings.
Authors: Kara Wools-Kaloustian; Silvester Kimaiyo; Lameck Diero; Abraham Siika; John Sidle; Constantin T Yiannoutsos; Beverly Musick; Robert Einterz; Kenneth H Fife; William M Tierney Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Melanie Lo; Saad B Omer; Leon Regensberg; Richard E Chaisson; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Sarah MacCarthy; Alexandra Mendoza-Graf; Uzaib Saya; Clare Samba; Josephine Birungi; Stephen Okoboi; Sebastian Linnemayr Journal: AIDS Care Date: 2019-05-28
Authors: Seth C Kalichman; Moira O Kalichman; Chauncey Cherry; Lisa A Eaton; Dean Cruess; Raymond F Schinazi Journal: J Acquir Immune Defic Syndr Date: 2016-09-01 Impact factor: 3.731
Authors: Laura B Whiteley; Elizabeth M Olsen; Kayla K Haubrick; Enyonam Odoom; Nicholas Tarantino; Larry K Brown Journal: Curr HIV/AIDS Rep Date: 2021-06-21 Impact factor: 5.071
Authors: Lora L Sabin; Nafisa Halim; Davidson H Hamer; Elizabeth M Simmons; Sivani Jonnalagadda; Anna Larson Williams; Harriet Chemusto; Allen L Gifford; Rachael Bonawitz; Philip Aroda; Mary DeSilva; Julia Gasuza; Barbara Mukasa; Lisa J Messersmith Journal: AIDS Behav Date: 2020-11
Authors: Jeffrey I Campbell; Angella Musiimenta; Bridget Burns; Sylvia Natukunda; Nicholas Musinguzi; Jessica E Haberer; Nir Eyal Journal: AIDS Care Date: 2018-12-09